GlassScriptPhysician profile
Jami L Mannle
NPI 1184857674
$6,581.98
in general payments reported to CMS, 2019-2025
20 companies · $964 in 2025
The $964 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $910 · 2022: $1,790 · 2023: $1,323 · 2024: $1,596 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,649 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,649.09 |
| Education | $233.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,205.90 | 2021-2025 | |
| Janssen Biotech, INC. | $736.52 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $554.07 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $453.75 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $380.08 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $310.58 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $304.26 | 2022-2025 | Sotyktu |
| Ucb, INC. | $262.39 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $238.30 | 2021-2025 | |
| Dermavant Sciences, INC. | $198.00 | 2022-2023 | Vtama |
| Leo Pharma INC. | $191.00 | 2021-2024 | Adbry |
| Genzyme Corporation | $163.18 | 2021-2024 | |
| Galderma Laboratories, L.P. | $123.47 | 2021-2024 | Aklief, Epsolay, Oracea |
| Arcutis Biotherapeutics, INC. | $123.11 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $107.05 | 2021-2023 | Winlevi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $62.23 | 2021-2024 | Dupixent |
| Mayne Pharma Commercial LLC | $39.89 | 2021-2024 | |
| Organon LLC | $32.62 | 2025 | Vtama |
| Biofrontera INC. | $15.59 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jami Mannle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.